Skip to main content
. 2018 Jan 27;10(2):35. doi: 10.3390/cancers10020035

Figure 1.

Figure 1

Forest plot demonstrating hazard ratio for phase III clinical trials in pancreatic cancer that included a control arm of gemcitabine monotherapy for a consistent comparison